Companies that have invested in mature RWE capabilities are seeing returns; others are behind. Results from Deloitte’s third RWE benchmarking study reveal how companies still building their capabilities can catch up:
- 94% of survey respondents believe using RWE in R&D will become important or very important to their organizations by 2022.
- Survey respondents expect a shift in the application of RWE in the next two to three years with the highest impact being in R&D, including supporting regulatory filings and augmenting clinical trials
- Most respondents expect a wide range of benefits from using RWE in R&D. So far, the biggest gains have come in the form of cost reduction in post-marketing commitments and executing clinical trials.
- 70% say that a lack of research-grade data is hindering RWE efforts in R&D. This emphasizes the importance of establishing strategic partnerships: More than 80% of surveyed companies are entering into strategic partnerships to access new sources of RWD.
- Almost all companies expect to increase investments in talent, technology, and external partnerships to strengthen their RWE capabilities.
About the Author: stuart.mccully
Stuart is the founder of Phoenix-RWR (www.phoenix-rwr.co.uk) and has 15+ years experience providing regulatory compliance solutions for real world studies, such as non-interventional studies. Stuart is best known for his 'NIS Considerations' reports he created through CHCUK
